Articles
FDA Approves Advair 250/50 for COPD
In April, the FDA approved Advair Diskus 250/50 for the reduction of
exacerbations in patients with chronic obstructive pulmonary disease (COPD) who
have a history of exacerbations.
The FDA also expanded the
use of Advair Diskus 250/50 to a broader patient population, which includes not
only patients with COPD associated with chronic bronchitis, but also emphysema
or both conditions.
Advair contains two
medicines, an inhaled corticosteroid (fluticasone propionate) and a long-acting
beta-agonist (salmeterol), that work together to improve lung function and
reduce exacerbations, two primary goals in the management of COPD.
